Gastroenterologie a hepatologie
type: channel
description: Gastroenterology and Hepatology is an official peer-reviewed journal of the Czech Society of Gastroenterology and the Czech Society of Hepatology, the Slovak Society of Gastroenterology and the Slovak Society of Hepatology, published by the Czech Medical Association of J. E. Purkyně by the publishing house Care Comm. It is published on 6× a year. The articles are published in Czech, Slovak and English. The journal has been published since 1999, its previous name was Czech and Slovak Gastroenterology and Hepatology (ISSN 1213-323X). Gastroenterology and hepatology are indexed in the following databases: SCOPUS, CHEMICAL TITLES, EXCERPTA MEDICA/EMBASE, CHEMICAL ABSTRACTS, INIS Atomindex, Food Science and Technology Abstracts, Bibliographia Medica Čechoslovaca, Index Copernicus.
publisher: Česká lékařská společnost JEP
language: en
publication name: Gastroenterologie a hepatologie
issn: 1804-7874
items: 8. kongres České gastroenterologické společnosti: abstrakta
items: 80th anniversary of the founding of the Czech Gastroenterological Society
items: Galerie „otců zakladatelů“ gastroenterologické společnosti – Profesor MUDr. Karel Herfort, DrSc. (23. 9. 1906 – 21. 1. 2000)
items: Správná odpověď na předchozí kvíz
items: The selection from international journals 5/2025
items: New developments in the treatment of primary biliary cholangitis
items: Disease clearance – a new horizon in ulcerative colitis
items: Guselkumab in the treatment of inflammatory bowel diseases
items: Colorectal cancer screening in Slovakia
items: Report on the progress of the call for proposals to support screening colonoscopy centers under the National Recovery Plan
items: Evaluation of the colorectal cancer screening program in the Czech Republic
items: Stereotactic body radiotherapy in the treatment of hepatocellular carcinoma
items: Clinical utility of EUS-guided sampling of solid pancreatic lesions: diagnostic spectrum, treatment strategies, and prognostic insights from a single center
items: Endoscopic management of a gastroesophageal anastomotic leak and refractory stricture following robotic Ivor Lewis esophagectomy for esophageal adenocarcinoma
items: Colorectal cancer screening
items: Gastrointestinal oncology
items: Doporučené postupy České gastroenterologické společnosti ČLS JEP pro diagnostickou a terapeutickou koloskopii – aktualizované vydání 2024
items: MUDr. Alenka Huslarová
items: Low serum deoxyribonuclease I activity is associated with antiTNF-alpha induced skin adverse events in patients with inflammatory bowel disease
items: Komentář ke článku „Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission“ (Clinical Infectious Diseases)
items: Hereditary diffuse gastric cancer
items: Pancreatic cancer surveillance in high-risk individuals Position statement of professional societies
items: 17th educational and discussion gastroenterology days
items: Diagnóza nízkého stupně dysplazie u pacientů s Barrettovým jícen - pravděpodobně "overdiagnosed"
items: Switch from original to bio­similar adalimumab SB-5 in patients with Crohn‘s disease – long-term results
items: Dia­gnosis and endoscopic intervention in rare MALT lymphoma of the proximal jejunum
items: Part 2 – Epidemiology of inflammatory bowel diseases in the Czech population: available data sources, prevalence of treated patients and overall mortality
items: Colorectal cancer screening program in the Czech Republic – 2021 quality indicators evaluation
items: IBD patient care – the clinical practice of gastroenterology outpatient centres in the Czech Republic
items: Guidelines for the administration of biological therapy in patients with inflammatory bowel diseases: 2nd edition

8. kongres České gastroenterologické společnosti: abstrakta
type: item
description: 8. kongres České gastroenterologické společnosti ČLS JEP 16.–18. října 2025 Clarion Congress Hotel Prague, Praha
subject: Abstrakta
  topic: section
rights: Copyright (c) 2025
date: 2026-04-14
publication date: 2026-04-14
starting page: 414
ending page: 432

80th anniversary of the founding of the Czech Gastroenterological Society
type: item
description: Termín konání osmého ročníku kongresu České gastroenterologické společnosti vychází téměř na den přesně s výročím založení naší odborné společnosti, k němuž došlo před 80 lety dne 25. 10. 1945. Rád bych zmínil atmosféru a několik zakládajících osobností, které u zrodu odborné společnosti stály. Rozvoj různých podoborů vnitřního lékařství ve 30. letech minulého století byl velmi intenzivní, avšak byl násilně přerušen válečnými lety 1938–1945. Krátce po skončení druhé světové války, a to již v červenci roku 1945, byla v knihovně propedeutické kliniky prof. Prusíka ve Všeobecné nemocnici v Praze, dnešní IV. interní kliniky, svolána schůze přípravného výboru s cílem založit samostatnou odbornou společnost, která se bude věnovat diagnostice a léčbě trávicích chorob a jater. Doc. Scheiner, člen gastroenterologické skupiny z I. interní kliniky ve Všeobecné nemocnici v Praze, na přípravné schůzi shrnul důvody pro založení nové odborné společnosti. Zároveň si přípravný výbor přál vydávat vlastní časopis, a proto byla založena pracovní skupina, jejímiž členy byli: dr. Mařatka, doc. Mašek, doc. Scheiner a dr. Herfort, která měla za úkol prozkoumat požadavky lékařů z klinické praxe, zda by vznik takového časopisu uvítali. Byl připraven a rozeslán dotazník. Na dalším setkání dne 7. 9. 1945 bylo konstatováno, že odpovědělo a souhlas vyjádřilo pouze 148 lékařů a mnozí, především pražští kolegové, vůbec neodpověděli. Limitem pro možnost založit nový časopis byl minimální počet souhlasů 200 a vyšší, a proto musela být tato aktivita odložena až na pozdější dobu. V dubnu 1947 vyšlo první číslo našeho časopisu pod názvem Gastro-enterologia Bohema. Nicméně při této druhé přípravné schůzi (7. 9. 1945) bylo určeno datum první plenární a zakládající schůze, která se uskutečnila dne 25. 10. 1945 v posluchárně III. interní kliniky Všeobecné nemocnice. Zde se sešel výkvět interní medicíny té doby, neboť zakládajícími členy byli nejen gastroenterologicky orientovaní internisté, ale také revmat…
subject: Abstrakta
  topic: section
creator: Milan Lukas
rights: Copyright (c) 2025
date: 2026-04-14
publication date: 2026-04-14
starting page: 411
ending page: 413

Galerie „otců zakladatelů“ gastroenterologické společnosti – Profesor MUDr. Karel Herfort, DrSc. (23. 9. 1906 – 21. 1. 2000)
type: item
description: Profesor Karel Herfort pocházel z významné lékařské rodiny, jeho otcem byl prof. Karel Herfort (1871–1940), význačný český psychiatr a zakladatel péče o mentálně postižené děti, který pracoval na počátku minulého století jako lékař v Ernestinu, v prvním ústavu pro mentálně postižené děti založeném ve Šternberském paláci na Hradčanech. Syn Karel Herfort vystudoval lékařskou fakultu v Praze a po promoci nastoupil na I. interní kliniku Všeobecné nemocnice u prof. Krystiana Hynka. Zde se záhy stal členem gastroenterologického týmu se zájmem o provádění endoskopických vyšetření, byl také přímým spolupracovníkem dalšího „otce zakladatele“ ČGS prof. Jiřího Scheinera. Ve 30. letech realizoval studijní pobyty u prof. Mountiera v Paříži, kde se seznámil se semiflexibilní gastroskopií. V roce 1945 byl u zrodu ČGS. O jeho významném postavení při založení a formování naší společnosti svědčí fakt, že zastával funkci vědeckého sekretáře. V roce 1951 přešel Karel Herfort z I. interní kliniky na fakultní polikliniku v Praze, kde založil interní oddělení a později Laboratoř gastroenterologie 1. lékařské fakulty v Praze. Na tomto pracovišti postupně budoval mladý tým spolupracovníků zaměřených na gastroenterologii. V roce 1956 byl jmenován profesorem vnitřního lékařství a interní oddělení fakultní polikliniky vedl až do roku 1973, kdy jej vystřídal v pozici šéfa jeho žák doc. P. Frič. Z této vynikající líhně vzešli v pozdějších letech hvězdy české gastroenterologické školy jako byl zmíněný prof. Přemysl Frič, doc. Jan Kotrlík, as. Hana Dvořáková a mnozí další. V průběhu 50. let se Herfortova odborná pozornost zaměřila na onemocnění pankreatu, byl autorem klasifikace pankreatitidy a také inicioval založení a provádění testů posuzujících zevně sekretorickou schopnost břišní slinivky. Jeho nejvýznamnější žák a jedna z největších postav české medicíny druhé poloviny 20. století prof. MUDr. Přemysl Frič, DrSc., jeho osobnost charakterizoval slovy Marka Twaina: „Always do right. This will g…
subject: Personal news
  topic: section
creator: Milan Lukas
rights: Copyright (c) 2025
date: 2026-04-14
publication date: 2026-04-14
starting page: 409
ending page: 409

Správná odpověď na předchozí kvíz
type: item
description: U pacientky se jednalo o sinus a presakrální absces jako dlouhodobý následek parciální dehiscence ileopouch-anální anastomózy, ke které došlo v časném pooperačním období. Komplikace (absces) byla bezprostředně po operaci řešena perkutánní drenáží pod CT kontrolou s následným zlepšením stavu pacientky, nicméně nezabránila vzniku chronického sinusu. Průběh sinusu směřoval od dorzálního okraje IPAA a k sakrální kosti, kde komunikoval s chronickým presakrálním abscesem velikosti cca 50 × 60 mm. Chronická pánevní sepse byla u pacientky odpovědná za vleklou klinickou symptomatologii v podobě nechutenství, intermitentních febrilních stavů, nočního pocení, časných urgencí k vyprázdnění pouche a významného hmotnostního úbytku. Řešení sinusu a presakrálního abscesu, které měly významný negativní dopad na kvalitu života pacientky a zhoršovaly funkčnost rekonstrukční střevní operce, je vždy komplikované a dlouhodobé. V úvahu připadají chirurgická nebo endoskopická řešení. Z chirurgických přístupů je to zavedení „endosponge“ do místa vnitřního ústí sinusu. Jiným řešením může být exstirpace pouche a s časovým odstupem vytvoření nové IPAA anastomózy (re-do pouch) nebo jen provedení diskonekce trávicí trubice se založením terminální ileostomie. Z endoskopických technik, které se mohou uplatnit, přichází v úvahu nově zaváděná endoskopická vakuová terapie nebo provedení sinusotomie. Tento nový endoterapeutický výkon byl zaveden do klinické praxe před několika lety v Clevelandu a spočívá v širokém protětí a otevření vnitřního ústí sinusu elektrokauterem a v propojení sinusu s dutinou pouche. Sinusový kanál byl u této pacientky dlouhý přes 60 mm s průměrem lumen okolo 10 mm. Široké otevření sinusu a spojení s lumen pouche zabránilo další progresi hnisavé retence v presakrálním prostoru a zároveň umožnilo, aby byla dutina v presakrálním prostoru postupně vyplněna granulační tkání. Provedení sinusotomie u této pacientky je možné zhlédnout na webových stránkách časopisu (www.csgh.info). E…
subject: Comments
  topic: section
creator: Milan Lukas
rights: Copyright (c) 2025
date: 2025-10-31
publication date: 2025-10-31
starting page: 407
ending page: 407

The selection from international journals 5/2025
type: item
description: Impact of complete vs. partial endoscopic healing on long-term outcomes in Crohn’s disease: a prospective multicenter study Yzet C, Brazier F, Derval E et al. J Crohn Colitis 2025; 19 (7): jjaf104. doi: 10.1093/ecco-jcc/jjaf104. Vliv úplného oproti částečnému endoskopickému hojení na dlouhodobé výsledky u Crohnovy choroby: prospektivní multicentrická studie Úvod: Doporučení STRIDE II uznávají endoskopické hojení (EH), definované skóre SES-CD ≤ 2, jako jeden z hlavních terapeutických cílů u Crohnovy choroby (CD). Úplné EH by mohlo snížit riziko dlouhodobých komplikací u CD. Cílem této studie bylo posoudit riziko dlouhodobých komplikací u CD v závislosti na stupni dosaženého EH. Metody: Byla provedena prospektivní multicentrická studie, která zahrnovala všechny pacienty s hodnocením EH (2019–2022) ve třech centrech, a následně byly porovnány výsledky pacientů s úplným EH (CDEIS = 0) s pacienty s částečným EH (CDEIS > 0, ale < 4). Primárním výstupním ukazatelem bylo terapeutické selhání (potřeba intenzifikace léčby, a/nebo zahájení kortikosteroidů, a/nebo hospitalizace související s CD, a/nebo resekce střeva, a/nebo vznik striktury/fistuly, a/nebo rozvoj perianální CD). Výsledky: Do studie bylo zahrnuto celkem 128 pacientů. Léčba trvala před provedením kontrolní koloskopie průměrně 12 měsíců, přičemž rozmezí se pohybovalo mezi 8,3 a 24,3 měsíci. Po průměrném sledování 22 měsíců (s rozmezím mezi 19 a 23 měsíci) zaznamenalo terapeutické selhání 40 pacientů, což představuje 31 % z celkového počtu. Riziko tohoto selhání bylo výrazně vyšší u pacientů s částečným endoskopickým hojením (25 vs. 43 %; p = 0,036). Stejně tak bylo u této skupiny vyšší riziko hospitalizace spojené s Crohnovou chorobou (2,5 vs. 17 %; p = 0,005), s hazardním poměrem 6,89 a 95% intervalem spolehlivosti (1,46–32,4), přičemž p = 0,015. Riziko resekce střeva, zahájení terapie kortikosteroidy a intenzifikace léčby se u pacientů s úplným a částečným hojením lišilo takto: 0 vs. 4,3 % (p = 0,13); 2,5 vs. 11…
subject: Comments
  topic: section
rights: Copyright (c) 2025
date: 2025-10-31
publication date: 2025-10-31
starting page: 403
ending page: 405

New developments in the treatment of primary biliary cholangitis
type: item
description: Primary biliary cholangitis is a chronic, immunologically mediated, progressive liver disease characterized by progressive destruction of small bile ducts, resulting in cholestasis, liver fibrosis with the development of liver cirrhosis and all of its complications. These ultimately lead to liver failure, resulting in death or the need for a liver transplant. Early and effective treatment is a key factor in influencing the prognosis. The disease mainly affects women, accounting for 90% of cases. Diagnosis is possible based on an elevation of serum alkaline phosphatase (ALP) above 1.5-times the normal level for 6 months and in combination with the presence of antimitochondrial antibodies (AMA) ≥ 1: 40 or specific antinuclear antibodies (ANA) sp100, gp210, or a combination of elevated serum ALP with typical histological findings found during liver biopsy. Although ursodeoxycholic acid (UDCA) remains the treatment of choice, unfortunately some patients do not tolerate this treatment or do not respond adequately to it. Second-line treatment is currently available – peroxisome proliferator-activated receptor (PPAR) agonists, delta (PPAR-) or dual agonists (PPAR-/). Seladelpar (PPAR-) and elafibranor (PPAR-/) are promising treatment alternatives due to their anti- -inflammatory and antifibrotic properties.
subject: Review article
  topic: section
subject: primary biliary cholangitis
  topic: keywords
subject: alkaline phosphatase
  topic: keywords
subject: AMA antibodies
  topic: keywords
subject: ANA antibodies
  topic: keywords
subject: ursodeoxycholic acid
  topic: keywords
subject: elafibranor
  topic: keywords
subject: seladelpar
  topic: keywords
creator: Libuse Husova
rights: Copyright (c) 2025
date: 2026-04-14
publication date: 2026-04-14
starting page: 396
ending page: 401
doi: 10.48095/ccgh2025396

Disease clearance – a new horizon in ulcerative colitis
type: item
description: Therapeutic targets in ulcerative colitis have evolved from symptomatic control to a treat-to-target strategy, where endoscopic remission has become a key objective. However, persistent histological activity in patients in endoscopic remission poses a risk of relapse, which has led to the proposal of a new, more ambitious goal – “disease clearance.” This concept represents a composite endpoint comprising of simultaneous achievement of clinical, endoscopic, and histological remission. Growing evidence confirms that achieving “disease clearance” is associated with significantly better long-term outcomes, including a lower risk of hospitalizations and surgery. Furthermore, landmark results from the VERDICT trial have shown that with a treat-to-target strategy using vedolizumab, this stringent target is achievable in up to 67.2% of patients at 48 weeks, particularly when treatment is initiated early. Thus, “disease clearance” represents a new horizon in the management of ulcerative colitis with the potential to alter the natural course of the disease. Although its implementation poses challenges, it shifts the treatment paradigm towards the complete suppression of inflammatory activity and personalized medicine.
subject: Review article
  topic: section
subject: ulcerative colitis
  topic: keywords
subject: disease clearance
  topic: keywords
subject: treat-to-target
  topic: keywords
subject: vedolizumab
  topic: keywords
subject: histological remission
  topic: keywords
creator: Igor Sturdik
creator: Anna Gojdicova
creator: Samuel Majna
creator: Jana Skubakova
creator: Zuzana Vrablicova
creator: Jozef Toth
creator: Tibor Hlavaty
rights: Copyright (c) 2025
date: 2026-04-14
publication date: 2026-04-14
starting page: 390
ending page: 395
doi: 10.48095/ccgh2025390

Guselkumab in the treatment of inflammatory bowel diseases
type: item
description: Guselkumab is a human monoclonal antibody IgG1 targeted to the IL-23p19 subunit engaging receptor CD64, inducing neutralization of IL-23, and capturing of IL-23 in the myeloid cells. Positive results from registration studies QUASAR and GALAXI allowed an approval of guselkumab for clinical practice in patients with moderately to severely active ulcerative colitis and Crohn’s disease. In these studies, a high safety drug profile was also confirmed. The same dosage for both diseases and subcutaneous induction significantly differentiate guselkumab from other anti-IL-23p19 inhibitors.
subject: Review article
  topic: section
subject: guselkumab
  topic: keywords
subject: anti-IL-23 therapy
  topic: keywords
subject: inflammatory bowel disease
  topic: keywords
subject: ulcerative colitis
  topic: keywords
subject: Crohn’s disease
  topic: keywords
creator: Milan Lukáš
rights: Copyright (c) 2025
date: 2026-04-14
publication date: 2026-04-14
starting page: 384
ending page: 389
doi: 10.48095/ccgh2025384

Colorectal cancer screening in Slovakia
type: item
description: Colorectal cancer (CRC) is one of the most common oncological diseases worldwide. The Slovak Republic ranks among the countries with high incidence of this malignancy. Organized screening reduces both the incidence and mortality of colorectal cancer. In recent years, a decline in age-standardized incidence and mortality rates has been observed in Slovakia. Colorectal cancer screening in Slovakia began in 2004. Since 2021, an active invitation system has been introduced, targeting individuals from the eligible population who have not participated in screening within the past two years. The target population for CRC screening in Slovakia includes individuals aged 50 to 75 years who are at average risk for the disease. Screening is performed either by a biennial immunochemical fecal occult blood test (FIT) in the general practitioner’s office or by a primary screening colonoscopy once every 10 years. Since the implementation of the active invitation system, there has been an increase in the number of FITs performed, as well as in the number of both screening and diagnostic colonoscopies in the target population. The most significant challenge of the CRC screening program in Slovakia is the lack of relevant data to assess its effectiveness and quality assurance.
subject: Original article
  topic: section
subject: colorectal cancer
  topic: keywords
subject: cancer screening
  topic: keywords
subject: fecal occult blood test
  topic: keywords
subject: colonoscopy
  topic: keywords
creator: Andrej Orsagh
creator: Roman Novota
creator: Adam Strbavy
creator: Jana Trautenberger Ricova
rights: Copyright (c) 2025
date: 2026-04-14
publication date: 2026-04-14
starting page: 373
ending page: 383
doi: 10.48095/ccgh2025373

Report on the progress of the call for proposals to support screening colonoscopy centers under the National Recovery Plan
type: item
description: Ministerstvo zdravotnictví (MZd) ve spolupráci s příslušnými řídicími komisemi průběžně hledá a realizuje různé kroky ke zvyšování kvality a efektivity screeningových programů v ČR. V rámci podpory kolorektálního screeningu vyvstal podnět k otevření dotační výzvy pro zlepšení přístrojového vybavení stávající sítě gastroenterologických pracovišť zapojených do screeningového programu.
subject: Others
  topic: section
creator: Veronika Rybenska
creator: Karel Hejduk
creator: Ondrej Majek
creator: Stepan Suchanek
rights: Copyright (c) 2025
date: 2026-04-14
publication date: 2026-04-14
starting page: 371
ending page: 372
doi: 10.48095/ccgh2025371

Evaluation of the colorectal cancer screening program in the Czech Republic
type: item
description: Introduction: Colorectal cancer (CRC) screening is a key tool for secondary prevention, whose effectiveness depends on population participation, accessibility of care, and quality of the examinations. Its impact is further determined by systematic data collection and analysis. High-quality data represent a fundamental pillar for monitoring ongoing screening, evaluating outcomes, and identifying weaknesses in the program. The aim is to demonstrate the benefits of data for optimizing the Czech program through two case studies. Methods: Data sources included the National Health Information System and the Database of Preventive Colonoscopies managed by the Institute of Health Information and Statistics of the Czech Republic, complemented with sociodemographic data from the Czech Statistical Office. Evaluation was carried out using screening quality indicators and a budget impact analysis focused on the change of age limits in screening. Results: The first case study shows a 33% decrease in CRC incidence and a 49% reduction in mortality since program implementation. Coverage of the target population has long remained around 30%. In 2020, a positive fecal occult blood test (FOBT) rose to 10%. The interval between a positive FOBT and follow-up colonoscopy corresponds to 3 months. The uptake of follow-up colonoscopy after a positive FOBT reaches 60%. The second case study revealed that expanding the eligible age range from 45–74 years will initially lead to a 5–6% increase in costs; however, from 2029 onwards, a reduction is expected. Discussion: The first study demonstrates the success of screening in reducing incidence and mortality, while also highlighting challenges such as low coverage, high FOBT positives, long waiting times for follow-up colonoscopy, and low uptake of follow-up colonoscopy. The second study found that expanding the age range will be cost-effective. Data confirm the benefits of screening for population health and indicate areas requiring further atten…
subject: Original article
  topic: section
subject: colorectal cancer
  topic: keywords
subject: adenoma
  topic: keywords
subject: screening
  topic: keywords
subject: colonoscopy
  topic: keywords
subject: fecal occult blood test
  topic: keywords
subject: quality indicators
  topic: keywords
subject: data
  topic: keywords
subject: statistical analysis
  topic: keywords
creator: Monika Ambrozova
creator: Petr Dvorak
creator: Renata Chloupkova
creator: Ondrej Ngo
creator: Veronika Rybenska
creator: Karel Hejduk
creator: Ladislav Dusek
creator: Ondrej Majek
rights: Copyright (c) 2025
date: 2025-10-31
publication date: 2025-10-31
starting page: 361
ending page: 370
doi: 10.48095/ccgh2025361

Stereotactic body radiotherapy in the treatment of hepatocellular carcinoma
type: item
description: Hepatocellular carcinoma (HCC) is one of the most serious complications of liver cirrhosis. Although early diagnosis allows for the use of curative approaches, many patients are not candidates for surgical treatment. In such cases, alternative methods of locoregional therapy gain importance. Stereotactic body radiotherapy (SBRT) is a specific form of external beam radiotherapy that enables highly precise irradiation of the target lesion with minimal impact on the surrounding tissue, achieving high rates of local disease control. Current EASL guidelines (2025) already include SBRT among recognized therapeutic options for selected patient groups, particularly when ablative techniques or TACE are not feasible. Clinical experience from our institution confirms good tolerability of SBRT and its suitability as a form of consolidative therapy. Although it remains a highly selective method with limited availability, SBRT represents a valuable complement to existing therapeutic modalities, and its role in HCC management is likely to grow in the future.
subject: Review article
  topic: section
subject: hepatocellular carcinoma
  topic: keywords
subject: liver cirrhosis
  topic: keywords
subject: radiosurgery
  topic: keywords
subject: stereotactic body radiotherapy
  topic: keywords
creator: Petr Hribek
creator: Ferdinand Trebicky
creator: Petr Urbanek
rights: Copyright (c) 2026 Gastroenterologie a hepatologie
date: 2026-04-14
publication date: 2026-04-14
starting page: 356
ending page: 360
doi: 10.48095/cccg2025356

Clinical utility of EUS-guided sampling of solid pancreatic lesions: diagnostic spectrum, treatment strategies, and prognostic insights from a single center
type: item
description: Background: Solid pancreatic lesions (SPLs) pose significant diagnostic and therapeutic challenges due to their high malignant potential and limited treatment options. Endoscopic ultrasound (EUS) -guided tissue sampling has become a cornerstone in their evaluation, offering minimally invasive access for histological confirmation. This study aimed to assess the clinical utility of EUS-guided biopsy for SPLs in a single center. Methods: We retrospectively analyzed patients who underwent EUS-guided tissue sampling for SPLs at the University Hospital Bratislava between 2018 and 2023. Exclusion criteria included cystic lesions or negative EUS findings. Data on demographics, lesion characteristics, sampling techniques, pathology, treatment modalities, and survival outcomes were collected. Diagnostic categories were stratified, and survival analyses were performed using Kaplan-Meier curves and Cox regression modeling. Results: Out of 747 EUS procedures, 159 met the inclusion criteria. The median patient age was 67 years; 62.3% were male. The most frequent diag- nosis was pancreatic adenocarcinoma (61.6%), followed by unspecified malignant lesions (10.1%), benign lesions (8.2%), and neuroendocrine tumors (7.5%). Malignant or potentially malignant lesions accounted for 83.9% of cases. EUS-guided biopsy was diagnostic in 90.6% of cases with no major complications recorded. Treatment (surgery, chemotherapy, or both) was administered to 48.4% of the patients. Surgical intervention and chemotherapy were both associated with significantly improved survival, with the best outcomes observed in patients receiving combined therapy. Surgery was the only independent predictor of reduced mortality (HR = 0.376; P = 0.002). Conclusion: EUS-guided sampling is a safe and effective tool for diagnosing SPLs, with high diagnostic yield and direct impact on treatment planning. Integration of histological findings into multidisciplinary management significantly influences prognosis, particularly…
subject: Original article
  topic: section
subject: endosonography
  topic: keywords
subject: pancreatic neoplasms
  topic: keywords
subject: biopsy
  topic: keywords
subject: fine-needle
  topic: keywords
subject: retrospective studies
  topic: keywords
subject: survival analysis
  topic: keywords
subject: adenocarcinoma
  topic: keywords
subject: multidisciplinary communication
  topic: keywords
creator: Tomas Koller
creator: Petra Vrbova
creator: Gabriel Holst
creator: Dana Dudova
creator: Iveta Meciarova
creator: Viliam Gal
creator: Miroslav Tomas
creator: Jozef Dolnik
rights: Copyright (c) 2025
date: 2025-10-15
publication date: 2025-10-15
starting page: 344
ending page: 355
doi: 10.48095/ccgh2025344

Endoscopic management of a gastroesophageal anastomotic leak and refractory stricture following robotic Ivor Lewis esophagectomy for esophageal adenocarcinoma
type: item
description: Background: An anastomotic leak following esophagectomy represents a severe, life-threatening complication. Over the past decade, endoscopic vacuum therapy (EVT) has become the preferred minimally invasive treatment modality. However, even after successful EVT, benign strictures may develop, which in some cases can be refractory to endoscopic dilation. Case presentation: We present the case of a 75-year-old female patient who underwent robot-assisted Ivor Lewis esophagectomy for esophageal adenocarcinoma and subsequently developed an extensive anastomotic dehiscence with leakage of luminal contents into the pleural cavity. The complication was successfully managed with EVT. During follow-up, the patient developed a refractory anastomotic stricture unresponsive to repeated balloon dilations, which was effectively resolved by the placement of a lumen-apposing metal stent (LAMS), resulting in rapid reintroduction of oral intake and significant improvement in the quality of life. Conclusion: This case illustrates the successful use of modern endoscopic techniques, specifically EVT and LAMS stenting, in managing severe complications after esophagectomy. Close multidisciplinary collaboration was crucial. The endoscopic approach allowed for complete healing of the defect without the need for surgical reintervention providing an effective solution for the refractory stricture, with minimal burden on the patient.
subject: Case report
  topic: section
subject: endoscopic vacuum therapy
  topic: keywords
subject: lumen-apposing metal stent
  topic: keywords
subject: refractory stricture
  topic: keywords
subject: esophagectomy
  topic: keywords
subject: anastomotic leak
  topic: keywords
subject: minimally invasive endoscopy
  topic: keywords
subject: esophageal cancer
  topic: keywords
creator: Katerina Kostalova
creator: Jan Csomor
creator: Zuzana Vackova
creator: Radek Pohnan
creator: Petr Urbanek
creator: Stepan Suchanek
rights: Copyright (c) 2025
date: 2025-10-15
publication date: 2025-10-15
starting page: 337
ending page: 343
doi: 10.48095/ccgh2025337

Colorectal cancer screening
type: item
description: Vážené kolegyně, vážení kolegové, dostává se k vám podzimní číslo časopisu Gastroenterologie a hepatologie, které je tradičně zaměřeno na gastrointestinální onkologii. Obsahuje skvělé články na téma EUS u solidních pankreatických lézí, stereotaktické radioterapie u hepatocelulárního karcinomu a endoskopické vakuové terapie u dehiscence anastomózy po resekci jícnu pro karcinom. Nicméně jako každý rok je dominantním tématem screening kolorektálního karcinomu (KRK). Podrobný článek autorů z Národního screeningového centra Ústavu zdravotnických informací (NSC ÚZIS ČR) (Ambrožová et al.) představuje analýzu nejnovějších dat z Národního screeningu KRK v České republice (ČR). Pozitivní zprávou je zejména pokračující trend poklesu incidence (32,5 %) a mortality (49,3 %) KRK od roku 2000. Zároveň je příznivé, že postupně dochází ke snižování pozitivity testů na okultní krvácení (TOKS), která v roce 2020 poprvé v historii překonala 10% hranici a dle posledních dostupných dat z roku 2024 došlo k jejímu poklesu na 8,7 %. To je dobrým krokem ke snížení počtu TOKS-pozitivních koloskopií, což může sekundárně vést ke zkrácení čekacích dob na toto vyšetření. Potěšitelné je, že od pandemie covidu-19 v roce 2020 postupně narůstá účast cílové populace na screeningu KRK a v loňském roce dosáhla hodnot zaznamenaných naposledy před 10 lety. Na druhou stranu v posledních letech stále klesají počty koloskopií po pozitivním TOKS, což je problém, který je nutné podrobně rozklíčovat. Nejvýznamnější změnou programu za mnoho posledních let bude úprava věkové hranice na 45–74 let věku. Opodstatnění tohoto kroku je v článku přesně zdokumentováno, ať už jde o nárust incidence a mortality KRK a vysoký podíl pokročilých stadií u mladších osob, nebo nízký podíl úmrtí na KRK u osob starších 75 let, či příznivé nákladově efektivní analýzy v dlouhodobém horizontu. Přípravné kroky této změny již běží a počátek nového designu programu je plánován na 1. 1. 2026. Další autoři z NSC ÚZIS ČR (Rybenská et al.) …
subject: Editorial
  topic: section
rights: Copyright (c) 2025
date: 2025-10-15
publication date: 2025-10-15
starting page: 328
ending page: 328
doi: 10.48095/d1hesg46

Gastrointestinal oncology
type: item
description: Vážení čitatelia Gastroenterologie a hepatologie, po horúcom lete prichádza jeseň, a k nej už tradične patrí v poradí piate tohtoročné číslo nášho časopisu. Tak ako každý rok je venované problematike gastrointestinálnej onkológie. Najväčšou onkologickou témou v gastroenterológii je skríning kolorektálneho karcinómu. Táto téma si tradične zaslúžila samostatný editoriál, ale mňa nesmierne teší, že po dlhšej prestávke vám prinášame správu o situácii na Slovensku. Pevne verím, že táto správa dr. Andreja Orságha bude mať pokračovanie v ďalších rokoch a bude predmetom horúcich odborných diskusií, ktoré pomôžu našu aktuálnu situáciu zlepšiť. Z ostatných menej nosných, ale rovnako dôležitých tém, ich v novom čísle nájdeme hneď niekoľko. Prvou je správa dr. Petra Hříbka o novej modalite liečby hepatocelulárneho karcinómu. Medzi potenciálne kuratívne modality patrili doposiaľ chirurgická resekcia, rádiofrekvenčná ablácia alebo transplantácia pečene. K nim v súčasnosti pribudla moderná neinvazívna metóda, tzv. stereotaktická rádioterapia. Autori prinášajú prehľad možného využitia a prvé vlastné skúsenosti pri liečbe pacientov. Druhou je správa z nášho pracoviska V. internej kliniky LF UK a UN Bratislava o klinickom využití EUS navigovanej tenko-ihlovej biopsie solídnych pankreatických lézií. Je to prvá správa zo Slovenska, ktorá dopĺňa v minulosti publikované skúsenosti z Českej republiky a prináša aj niekoľko unikátnych pohľadov. Metóda sa ukazuje nielen ako presný diagnostický nástroj, ale ukázalo sa, že má aj silný prognostický význam. Naviac, ak u malígnych lézií, ktorých bolo takmer 84 %, došlo ku nasadeniu cielených liečebných modalít, tieto mali pre pacientov prospech vo forme zlepšeného celkového prežívania. Treťou je prezentácia dr. Kateřiny Košťálovej, ktorá preberá kazuistiku 75-ročnej ženy po ezofagektómii pre adenokarcinóm, u ktorej sa objavila pomerne raritná kombinácia komplikácií vo forme anastomotickej dehiscencie, ktorej hojenie spôsobilo refraktérnu anastomo…
subject: Editorial
  topic: section
rights: Copyright (c) 2026 Gastroenterologie a hepatologie
date: 2026-04-14
publication date: 2026-04-14
starting page: 327
ending page: 327
doi: 10.48095/gav1ca31

Doporučené postupy České gastroenterologické společnosti ČLS JEP pro diagnostickou a terapeutickou koloskopii – aktualizované vydání 2024
type: item
subject: Others
  topic: section
creator: Přemysl Falt
creator: Jiří Cyrany
creator: Lumír Kunovský
creator: Ondřej Urban
creator: Martin Bortlík
creator: Stanislav Rejchrt
creator: Petr Vítek
creator: Kateřina Kamarádová
creator: Tomáš Grega
creator: Štěpán Suchánek
creator: Martin Hutyra
creator: Vít Navrátil
creator: Barbora Pipek
creator: Marcela Kopáčová
creator: Robert Procházka
creator: Martin Stašek
creator: Ivana Mikoviny Kajzrlíková
creator: Radek Kroupa
creator: Ilja Tachecí
rights: Copyright (c) Array
date: 2024-06-26
publication date: 2024-06-26
starting page: 197
ending page: 197
doi: 10.48095/ccgh2024197

MUDr. Alenka Huslarová
type: item
subject: Personal news
  topic: section
subject: gastroenterology
  topic: keywords
creator: Zdena Zádorová
rights: Copyright (c) Array
date: 2014-10-13
publication date: 2014-10-13
starting page: 194
ending page: 194

Low serum deoxyribonuclease I activity is associated with antiTNF-alpha induced skin adverse events in patients with inflammatory bowel disease
type: item
description: Background: A significant proportion of inflammatory bowel disease (IBD) patients develop skin complications during infliximab or adalimumab therapy. Both drugs are thoughtto act via induction of apoptosis in activated inflammatory cells. Deoxyribonuclease (DNase) I is endonuclease hydrolyzing double-stranded DNA during apoptosis and its deficiency has been implicated in several autoimmune disorders. Aim: To assess activity of DNase I in patients with IBD and to identify its impact together with other factors on development of skin immunopathological complications of biological therapy. Methods: IBD patients treated with infliximab or adalimumab at our centre from 2007-2009 were studied retrospectively for occurrence of skin non-infectious complications during this treatment and assessed for DNase I activity. A random sample of IBD patients treated with biological therapy without skin complications was also assessed. Serum was used to determine DNase I activity by enzyme-linked immunosorbent assay. Results: During the study period 313 patients with IBD were treated with biological therapy. Of them, 43 patients experienced non-infectious skin complications. 95 IBD patients on biological therapy without skin complications were also included. Univariate analysis identified female gender, adalimumab therapy, no concomitant corticosteroids and low DNase I activity as risk factors for skin complications. In multivariate analysis only low activity of DNase I (OR 0.45; 95% CI 0.29-0.71; p < 0.001) and adalimumab therapy (OR 30.8; 95% CI 6.87-138.16; p < 0.001) were associated with skin adverse events. Conclusions: Low DNase I activity may be a risk factor for development of immune-mediated skin complications during biological therapy in patients with IBD.
subject: Original article
  topic: section
subject: adalimumab
  topic: keywords
subject: inflammatory bowel disease
  topic: keywords
subject: infliximab
  topic: keywords
subject: biological therapy
  topic: keywords
subject: financování organizované
  topic: keywords
subject: lidé
  topic: keywords
subject: monoclonal antibodies
  topic: keywords
subject: mužské pohlaví
  topic: keywords
subject: retrospective study
  topic: keywords
subject: risk factors
  topic: keywords
subject: statistika jako téma
  topic: keywords
subject: TNF-alfa
  topic: keywords
subject: ženské pohlaví
  topic: keywords
subject: C-reaktivní protein
  topic: keywords
subject: deoxyribonukleasa I
  topic: keywords
subject: ELISA
  topic: keywords
subject: kožní nemoci
  topic: keywords
subject: multivariační analýza
  topic: keywords
subject: reprodukovatelnost výsledků
  topic: keywords
subject: retrospektivní studie
  topic: keywords
subject: rizikové faktory
  topic: keywords
creator: Karin Malíčková
creator: Dana Ďuricová
creator: Martin Bortlík
creator: Viktor Komárek
creator: Naděžda Machková
creator: Arnošt Komárek
creator: Ivana Janatková
creator: Milan Lukáš
rights: Copyright (c) Array
date: 2014-10-13
publication date: 2014-10-13
starting page: 31
ending page: 31

Komentář ke článku „Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission“ (Clinical Infectious Diseases)
type: item
subject: Comments
  topic: section
creator: Jan Král
rights: Copyright (c) Array
date: 2022-12-19
publication date: 2022-12-19
starting page: 512
ending page: 512
doi: 10.48095/ccgh2022512

Hereditary diffuse gastric cancer
type: item
description: Hereditary diffuse gastric cancer (HDGC) is an inherited form of the diffuse type of gastric cancer and a highly invasive type of tumour. Approximately 10% of patients with gastric cancer showfamiliar clustering and 3% autosomal dominance with a high HDGC penetration. It is an autosomal dominant inherited cancer syndrome in which affected individuals develop a diffuse type of gastric cancer at a young age. Inactivating mutations in the E-cadherin gene CDH1 have been identified in 30-50% of patients. CDH1 mutations carriers have an approximately 70% lifetime risk for developing diffuse gastric cancer (DGC) and affected women carry an additional 20-40% risk for developing lobular breast cancer. Common white light endoscopic surveillance is ineffective in identifying early HDGC. Gene-directed prophylactic total gastrectomy is currently being offered for CDH1 mutations carriers. Total gastrectomy is offered to patients who are five years younger than the youngest family member who developed gastric cancer, usually to patients older than 20. When refusing surgery, intensive endoscopic surveillance twice a year with multiple "protocol-based" and targeted biopsies combined with chromoendoscopy or NBI respectively are offered as an alternative option. Preventive total gastrectomy currently remains the only curative option for patients with HDGC.
subject: Review article
  topic: section
subject: endoscopic treatment
  topic: keywords
subject: lidé
  topic: keywords
subject: mutace
  topic: keywords
subject: stomach neoplasms
  topic: keywords
subject: endoscopy
  topic: keywords
subject: gastrektomie
  topic: keywords
subject: genetické nemoci vrozené
  topic: keywords
subject: genetické testování
  topic: keywords
creator: Peter Mlkvý
creator: Michal Fritzmann
creator: Peter Minárik
creator: Katarína Macháleková
creator: Ivan Čavarga
creator: Anton Mateášik
rights: Copyright (c) Array Gastroenterologie a hepatologie
date: 2014-10-13
publication date: 2014-10-13
starting page: 365
ending page: 365
doi: 10.48095/p6wjx881

Pancreatic cancer surveillance in high-risk individuals Position statement of professional societies
type: item
subject: Others
  topic: section
subject: high-risk individuals
  topic: keywords
subject: pancreatic carcinoma
  topic: keywords
subject: screening
  topic: keywords
subject: surveillance
  topic: keywords
rights: Copyright (c) Array
date: 2023-12-28
publication date: 2023-12-28
starting page: 529
ending page: 529
doi: 10.48095/ccgh2023529

17th educational and discussion gastroenterology days
type: item
subject: Event report
  topic: section
creator: Ondřej Urban
rights: Copyright (c) Array
date: 2023-03-03
publication date: 2023-03-03
starting page: 61
ending page: 61

Diagnóza nízkého stupně dysplazie u pacientů s Barrettovým jícen - pravděpodobně "overdiagnosed"
type: item
subject: Others
  topic: section
subject: Barrett’s oesophagus
  topic: keywords
subject: esophageal neoplasms
  topic: keywords
subject: gastrointestinální endoskopie
  topic: keywords
subject: hyperplazie
  topic: keywords
subject: lidé
  topic: keywords
subject: prekancerózy
  topic: keywords
subject: senzitivita a specificita
  topic: keywords
subject: výsledky a postupy - zhodnocení (zdravotní péče)
  topic: keywords
creator: Jan Martínek
rights: Copyright (c) Array
date: 2014-10-13
publication date: 2014-10-13
starting page: 403
ending page: 403

Switch from original to bio­similar adalimumab SB-5 in patients with Crohn‘s disease – long-term results
type: item
description: Background and aims: Originator-adalimumab, an established treatment for patients with Crohn‘s disease (CD) showed no difference in efficacy or adverse events vs the adalimumab biosimilar SB5 (SB5-adalimumab) over 10 weeks of treatment. To understand the long-term efficacy of SB5-adalimumab in CD, patients who switched from originator-adalimumab to SB5-adalimumab were compared to a cohort who remained on originator-adalimumab over a follow up of 104 weeks. Methods: In this analysis, data on patients ≥18 years and diagnosed with CD treated at the IBD ISCARE centre were collected prospectively between July 2018 and January 2021. Clinical disease activity as measured by Harvey-Bradshaw index (HBI) at Week 52 was the primary outcome, while C-reactive protein (CRP), faecal calprotectin (FC), adalimumab trough levels in Weeks 10, 26, 52, 78, and 104, adverse events leading to therapy withdrawal, and persistence on treatment were secondary outcomes. To ensure comparable treatment cohorts, patients were propensity score matched (PSM) for age, gender, diagnosis, and disease activity. Results: A total of 54 patients were matched according to the given criteria in each group. At Week 52, the mean [SD] HBI score was 3.2 (2.5) in the originator-adalimumab group and 4.0 (3.6) in SB5-adalimumab patients (difference [95% CI] –0.78 [–2.8, 1.3]). Similarly, no clinically significant differences in CRP, FC, or trough levels were noted between originator-adalimumab and SB5-adalimumab cohorts through Week 52. The Kaplan-Meier estimates (95% CI) of patients remaining on treatment for the originator-adalimumab vs SB5-adalimumab cohorts were 0.870 (0.785–0.965) vs 0.648 (0.533–0.789) at Week 52. Conclusions: These long-term study results in CD patients after a non-medical switch from originator-adalimumab to SB5-adalimumab showed that the biosimilar SB5 had similar therapeutic effects as originator-adalimumab in terms of clinical disease activity, biological parameters, and pharmacokinetic…
subject: Original article
  topic: section
subject: biologic therapy
  topic: keywords
subject: bio­similární adalimumab SB-5
  topic: keywords
subject: Crohn’s disease
  topic: keywords
subject: inflammatory bowel disease
  topic: keywords
creator: Milan Lukáš
creator: Martin Kolář
creator: J. Reissigová
creator: Milan Lukáš jr.
creator: Martin Vašátko
creator: Veronika Hrubá
creator: Naděžda Machková
creator: Kateřina Černá
creator: Dana Ďuricová
rights: Copyright (c) Array
date: 2021-06-26
publication date: 2021-06-26
starting page: 242
ending page: 242
doi: 10.48095/ccgh2021242

Dia­gnosis and endoscopic intervention in rare MALT lymphoma of the proximal jejunum
type: item
description: Extranodal lymphoma from the marginal zone mucosa-associated lymphoid tissue (MALT lymphoma) is one of the primary extranodal non-Hodgkin‘s lymphomas with low degrees of malignancy but with the risk of spreading to distant locations in the body. B-lymphomas are sometimes associated with other diseases (eg. Helicobacter pylori and Campylobacter jejuni infections or inflammatory bowel disease). B-lymphomas may manifest with a variety of clinical signs, from dyspeptic syndrome with malabsorption and weight loss to ileus or massive gastrointestinal bleeding. Diagnosis is based on the clinical condition and the results of laboratory tests and imaging techniques, while endoscopy is the essential procedure for visualizing the tumor mass and collecting a biopsy sample to determine the definitive histopathological diagnosis. MALT lymphoma treatment is managed by oncologists and includes chemotherapy and/or radiotherapy, with resection indicated in rare cases. In this case report we present an elderly female patient who was referred to our IBD centre for non-specific abdominal pain with a positive fecal occult blood test. Computed tomography (CT) examination was used before endoscopy and showed an infiltration of the splenic flexure by an unspecified mass, a subsequent colonoscopy showed intact mucosa of the colon, including the terminal ileum. In the second reading of the CT scan the location of the infiltrate was identified more specifically as the area of the proximal jejunum and jejunal mesentery. Subsequent upper endoscopy revealed a stenosing exulcerated tumor in the proximal jejunum, with the stenosis impassable even for a pediatric colonoscope. The diagnosis of MALT lymphoma was confirmed by a histological examination of the biopsied tissue. A follow-up upper endoscopy was performed after the patient had completed her oncological treatment (chemotherapy in combination with radiotherapy), showing the presence of stenosis at the proximal jejunum, still impassable for th…
subject: Case report
  topic: section
subject: intestinal perforation
  topic: keywords
subject: lymfom z B-buněk marginální zóny
  topic: keywords
subject: MALT
  topic: keywords
subject: stricture
  topic: keywords
creator: Tomáš Drašar
creator: Lenka Nedbalová
creator: Tomáš Zajíc
creator: Tomáš Jirásek
rights: Copyright (c) Array
date: 2021-11-04
publication date: 2021-11-04
starting page: 432
ending page: 432
doi: 10.48095/ccgh2021432

Part 2 – Epidemiology of inflammatory bowel diseases in the Czech population: available data sources, prevalence of treated patients and overall mortality
type: item
subject: Editorial
  topic: section
creator: Ladislav Dušek
creator: Ondřej Ngo
creator: Ondřej Májek
creator: Jan Mužík
creator: Jakub Kubát
creator: Milan Blaha
creator: Jiří Jarkovský
creator: Milan Lukáš
rights: Copyright (c) Array
date: 2019-04-27
publication date: 2019-04-27
starting page: 163
ending page: 163
doi: 10.14735/amgh2019163

Colorectal cancer screening program in the Czech Republic – 2021 quality indicators evaluation
type: item
description: Background: Compared to other European countries, the Czech Republic has long been one of the countries with high rates of incidence and mortality of colorectal cancer. The screening program was implemented in 2000 and has become an essential part of prevention policy in the Czech Republic. Continuous monitoring of the entire screening process is necessary to ensure high quality and the resulting success of the program. The aim of the paper is to present the current results of the National Colorectal Cancer Screening Program using selected indicators in accordance with established recommendations. Material and Methods: The analysis was performed on data on preventive colonoscopies performed in Centers for screening colonoscopy (Centers) in 2021, with selected performance indicators being evaluated (number of preventive colonoscopies, adequate bowel preparation, caecal intubation rate and adenoma detection rate). The resulting performance indicators were evaluated by the published recommendations of the Czech Gastroenterological Society to point to the results of the program as a whole, not to assess individual Centers. Results: The majority (94.7%) of the Centers achieved the basic performance indicator (number of preventive colonoscopies). The performance indicator of adequate bowel preparation was met by 83.6% of Centers (the average proportion of colonoscopies with adequate bowel preparation in the Czech Republic is 93.8%). The optimal proportion of caecal intubation (90.0%) was reached by 87.2% of Centers in 2021. Only 16 Centers (8.5%) did not meet the adenoma detection rate indicator, but a high variability was observed across the Centers (11.6% to 68.2%) – a similar situation was observed in evaluation by gender and indication. A relatively low adenoma detection rate in follow-up colonoscopies after positive FOBT could be related to high and variable FOBT, which may indicate redundant colonoscopies and overburden the Centers. Conclusion: Some Centers do not r…
subject: Original article
  topic: section
subject: colonoscopy
  topic: keywords
subject: colorectal cancer
  topic: keywords
subject: performance indicators
  topic: keywords
subject: screening
  topic: keywords
creator: Renata Chloupková
creator: Ondřej Ngo
creator: Štěpán Suchánek
creator: Miroslav Zavoral
creator: Karel Hejduk
creator: Ondřej Májek
creator: Lucie Martykánová
rights: Copyright (c) Array
date: 2022-10-19
publication date: 2022-10-19
starting page: 379
ending page: 379
doi: 10.48095/ccgh2022379

IBD patient care – the clinical practice of gastroenterology outpatient centres in the Czech Republic
type: item
description: The number of patients with inflammatory bowel disease (Crohn’s disease and ulcerative colitis) has increased steadily. Gastroenterology outpatient centres are playing a very important role in care for these patients. Clinical practice of care for patients suffering from idiopathic inflammatory bowel diseases at these centres was assessed in our study. The data was obtained using a structured questionnaire comprising four major topics (characteristics of the centre, diagnosis, therapy and monitoring of patients). The obtained data was compared with the local and international recommendations and showed high professional standards of care.
subject: Original article
  topic: section
subject: Crohn’s disease
  topic: keywords
subject: diagnosis
  topic: keywords
subject: inflammatory bowel disease
  topic: keywords
subject: monitoring of patients
  topic: keywords
subject: outpatient care
  topic: keywords
subject: treatment
  topic: keywords
subject: ulcerative colitis
  topic: keywords
creator: Luděk Hrdlička
rights: Copyright (c) Array
date: 2014-12-01
publication date: 2014-12-01
starting page: 456
ending page: 456
doi: 10.14735/amgh2014456

Guidelines for the administration of biological therapy in patients with inflammatory bowel diseases: 2nd edition
type: item
subject: Guidelines
  topic: section
subject: biological therapy
  topic: keywords
subject: Crohn’s disease
  topic: keywords
subject: inflammatory bowel disease
  topic: keywords
subject: léková alergie
  topic: keywords
subject: lidé
  topic: keywords
subject: monitorování léků
  topic: keywords
subject: monoclonal antibodies
  topic: keywords
subject: nežádoucí reakce na léčiva
  topic: keywords
subject: pregnancy
  topic: keywords
subject: risk factors
  topic: keywords
subject: ulcerative colitis
  topic: keywords
subject: adalimumab
  topic: keywords
subject: infliximab
  topic: keywords
subject: nežádoucí účinky léčiv
  topic: keywords
subject: rizikové faktory
  topic: keywords
subject: ulcerózní kolitida
  topic: keywords
creator: Martin Bortlík
creator: Dana Ďuricová
creator: Pavel Kohout
creator: Michal Konečný
creator: Jana Koželuhová
creator: Aleš Novotný
creator: Vladimír Zbořil
creator: Lucie Prokopová
creator: Tomáš Douda
creator: Jiří Stehlík
creator: Olga Shonová
creator: Karel Mareš
creator: Luděk Hrdlička
creator: Petra Matějková
creator: Zuzana Šerclová
creator: Lenka Nedbalová
creator: Marie Tomanová
creator: Martin Liberda
creator: Jiří Bronský
creator: Pavel Drastich
creator: Milan Lukáš
creator: Katarína Mitrová
rights: Copyright (c) Array
date: 2014-10-13
publication date: 2014-10-13
starting page: 22
ending page: 22